Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.

Koltai K, Kesmarky G, Feher G, Tibold A, Toth K.

Int J Mol Sci. 2017 Aug 18;18(8). pii: E1803. doi: 10.3390/ijms18081803. Review.

2.

Protein kinase A activation by the anti-cancer drugs ABT-737 and thymoquinone is caspase-3-dependent and correlates with platelet inhibition and apoptosis.

Rukoyatkina N, Butt E, Subramanian H, Nikolaev VO, Mindukshev I, Walter U, Gambaryan S, Benz PM.

Cell Death Dis. 2017 Jun 29;8(6):e2898. doi: 10.1038/cddis.2017.290.

3.

Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.

Zhou Y, Wang Y, Wu Y, Huang C, Yan H, Zhu W, Xu W, Zhang L, Zhu J.

BMC Cardiovasc Disord. 2017 Jun 15;17(1):157. doi: 10.1186/s12872-017-0582-6.

4.

Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.

Kukula K, Klopotowski M, Kunicki PK, Jamiolkowski J, Debski A, Bekta P, Polanska-Skrzypczyk M, Chmielak Z, Witkowski A.

BMC Cardiovasc Disord. 2016 Dec 8;16(1):252.

5.

Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms.

Sedat J, Chau Y, Gaudart J, Sachet M, Beuil S, Lonjon M.

Interv Neuroradiol. 2017 Feb;23(1):52-59. doi: 10.1177/1591019916669090. Epub 2016 Oct 22.

PMID:
27760885
6.

Can erythrocytes release biologically active NO?

Benz PM, Fleming I.

Cell Commun Signal. 2016 Sep 17;14(1):22. doi: 10.1186/s12964-016-0145-y.

7.

Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study.

Forni Ogna V, Menetrey I, Muller O, Tousset E, Guihard L, Fontana P, Eeckhout E, Eap CB, Vrijens B, Burnier M, Wuerzner G.

Br J Clin Pharmacol. 2016 Dec;82(6):1486-1497. doi: 10.1111/bcp.13071. Epub 2016 Sep 9.

PMID:
27447737
8.

The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions.

Tekkeşin Aİ, Kaya A, Çakıllı Y, Türkkan C, Hayıroğlu Mİ, Borklu EB, Kalenderoğlu K, Gümüşdağ A, Yıldırımtürk Ö, Bozbeyoğlu E, Tatlısu MA, Alper AT.

Anatol J Cardiol. 2016 Dec;16(12):967-973. doi: 10.14744/AnatolJCardiol.2016.6855. Epub 2016 Apr 25.

9.

Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.

Xu L, Hu XW, Zhang SH, Li JM, Zhu H, Xu K, Chen J, Li CJ.

Chin Med J (Engl). 2016 Apr 20;129(8):984-91. doi: 10.4103/0366-6999.179786.

10.

Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.

Yi X, Lin J, Wang Y, Zhou Q, Wang C, Cheng W, Chi L.

J Atheroscler Thromb. 2016 Oct 1;23(10):1188-1200. Epub 2016 Mar 8.

11.

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Winter MP, Koziński M, Kubica J, Aradi D, Siller-Matula JM.

Postepy Kardiol Interwencyjnej. 2015;11(4):259-80. doi: 10.5114/pwki.2015.55596. Epub 2015 Jan 12. Review.

12.

Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.

Li P, Yang Y, Chen T, Liu Y, Cao A, Liu J, Wang Z, Zhao X, Qin Y, Ma L.

Sci Rep. 2015 Sep 9;5:13789. doi: 10.1038/srep13789.

13.

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use.

Norgard NB, DiNicolantonio JJ.

Ther Adv Chronic Dis. 2015 Jul;6(4):204-18. doi: 10.1177/2040622315584113. Review.

14.

A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.

Rath PC, Chidambaram S, Rath P, Dikshit B, Naik S, Sahoo PK, Das B, Mahalingam M, Khandrika L, Jain J.

Indian Heart J. 2015 Mar-Apr;67(2):114-21. doi: 10.1016/j.ihj.2015.03.017. Epub 2015 Apr 27.

15.

State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.

Kumbhani DJ, Marso SP, Alvarez CA, McGuire DK.

Curr Cardiovasc Risk Rep. 2015 Jan;9:4.

16.

Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.

Tang XF, Han YL, Zhang JH, Wang J, Zhang Y, Xu B, Gao Z, Qiao SB, Chen J, Wu Y, Chen JL, Gao RL, Yang YJ, Yuan JQ.

Chin Med J (Engl). 2015 Mar 20;128(6):774-9. doi: 10.4103/0366-6999.152611.

17.

Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.

Zhu HC, Li Y, Guan SY, Li J, Wang XZ, Jing QM, Wang ZL, Han YL.

J Geriatr Cardiol. 2015 Jan;12(1):23-9. doi: 10.11909/j.issn.1671-5411.2015.01.003.

18.

A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.

Koul S, Andell P, Martinsson A, Smith JG, Scherstén F, Harnek J, Götberg M, Norström E, Björnsson S, Erlinge D.

BMC Cardiovasc Disord. 2014 Dec 16;14:189. doi: 10.1186/1471-2261-14-189.

19.

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.

Christ G, Siller-Matula JM, Francesconi M, Dechant C, Grohs K, Podczeck-Schweighofer A.

BMJ Open. 2014 Oct 31;4(10):e005781. doi: 10.1136/bmjopen-2014-005781.

20.

Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.

Timur AA, Murugesan G, Zhang L, Barnard J, Bhatt DL, Kottke-Marchant K.

Thromb Res. 2014 Jul;134(1):96-104. doi: 10.1016/j.thromres.2014.04.023. Epub 2014 Apr 29.

Supplemental Content

Support Center